What to Expect When Johnson & Johnson Reports Tuesday

By Chris Lange Updated Mar 13, 10:19PM EDT · Published Oct 15, 10:15AM EDT

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Johnson & Johnson (NYSE: JNJ) is scheduled to report its third-quarter financial results before the markets open on Tuesday. The consensus estimates are calling for $2.03 in earnings per share (EPS) and $20.05 billion in revenue. The same period of last year reportedly had $1.90 in EPS and $19.65 billion in revenue.

The firm’s strong second-quarter results reflected double-digit growth in its Pharmaceutical business and the accelerating sales momentum in its Medical Devices business, driven by the continued growth of its market-leading products and strategic new launches.

Alex Gorsky, board chair and chief executive, commented in the second quarter:

We remain focused on investing in innovation and meeting the needs of our customers by delivering innovative products and solutions that position the company to deliver long-term, sustainable growth. Our talented J&J colleagues are united in our efforts to address some of the most critical health and consumer needs of people around the world.

[nativounit]

Also at that time, Johnson & Johnson updated its full-year guidance. The company now expects to see EPS in the range of $8.07 to $8.17 and revenues between $80.5 billion and $81.3 billion. The consensus estimates now are $8.15 in EPS and revenue of $81.23 billion for the year.

Overall, Johnson & Johnson has underperformed the broad markets, with the stock down 2% in the past 52 weeks. In just 2018 alone, the stock is down 4%.

A few analysts weighed in on Johnson & Johnson ahead of the report:

Credit Suisse has a Buy rating with a $149 price target.
Wells Fargo has an Outperform rating and a $160 target.
Jefferies has a Buy rating with a $145 price target.
Goldman Sachs has a Neutral rating.

Johnson & Johnson shares were last seen trading at $133.95, with a consensus analyst price target of $144.32 and a 52-week trading range of $118.62 to $148.32.

[recirclink id=498817]

[wallst_email_signup]

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.